Monoclonal antibody JST-010 + Placebo

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults

Conditions

Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults

Trial Timeline

May 16, 2025 → Oct 1, 2027

NCT ID

NCT06943378

About Monoclonal antibody JST-010 + Placebo

Monoclonal antibody JST-010 + Placebo is a phase 1 stage product being developed by Evotec for Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06943378. Target conditions include Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06943378	Phase 1	Recruiting	May 16, 2025	Oct 1, 2027	Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults

Competing Products

7 competing products in Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults

See all competitors

Product	Company	Stage	Hype Score
Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF	Gilead Sciences	Phase 3	76
Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)	Gilead Sciences	Phase 2	51
Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only)	Gilead Sciences	Phase 3	76
Lenacapavir Injection + Lenacapavir Tablet	Gilead Sciences	Phase 3	76
Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF)	Gilead Sciences	Phase 2	51
F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo	Gilead Sciences	Phase 3	76
Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF)	Gilead Sciences	Phase 2	51

Other Products from Evotec

EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)Phase 2

EVT 201Phase 2

EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus open label Nicotine ReplacementPhase 2

EVT 201Phase 2

EVT 101 + EVT 101 + placeboPhase 1